Register for IndieBio SF’s VC-Founder Meetings + Demo Day  – Week of January 26, 2026

Learn more about investing in Liberum Bio

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
We don’t spam. Our Privacy Policy and Cookie Policy apply. The site is protected by reCAPTCHA.
Liberum Bio
Liberum Bio
Desktop protein manufacturing with the push of a button
CONTACT COMPANY
INVESTOR INQUIRIES
Industrial Bio Medtech IBSF10 2020 Pre-Seed Canada
* Data source: Crunchbase
Founded
2020
Employees*
2-10
Funding to Date*
undisclosed
Website
liberumbio.com
* Data source: Crunchbase
Aidan Tinafar, CEO
While Twist and Illumina dominate the DNA sequencing and synthesis markets, there is still a bottleneck in recombinant protein production. We want to fill that void.
By 2025, the recombinant protein market is expected to reach $400 billion.

Today, to produce any sort of custom recombinant protein, it takes weeks. This dramatically slows down scientists’ ability to test, iterate, and improve. Liberum’s affordable, benchtop protein printer will cut that time down to a few hours.

Team
Ryan Fobel
Co-Founder
x-logo
Keith Pardee
Co-Founder
Aidan Tinafar
Co-Founder and CEO
x-logo
Company News
BetaKit | July 24, 2023
Liberum raises $1.8 million for ‘protein synthesis as a service’ | BetaKit

The Toronto-based biotech startup calls its platform “protein synthesis as a service.”
TechCrunch | October 27, 2020
Next-gen skincare, silk without spiders and pollution for lunch: Meet the biotech startups pitching at IndieBio’s Demo Day

Biotech can often, and sometimes literally, fly over our heads. However, the pandemic has shown an increased need for investment and focus on solutions that work on human and planetary health. For IndieBio, a science and biotech accelerator run by VC firm SOSV, this unprecedented year offered high …